» Articles » PMID: 16288032

MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3beta-mediated Phosphorylation and Degradation of Beta-catenin

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Nov 17
PMID 16288032
Citations 143
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulation of beta-catenin is of importance to the development of diverse human malignancies. The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and associates with beta-catenin. However, the functional significance of the MUC1-beta-catenin interaction is not known. Here, we show that MUC1 increases beta-catenin levels in the cytoplasm and nucleus of carcinoma cells. Previous studies have shown that glycogen synthase kinase 3beta (GSK3beta) phosphorylates beta-catenin and thereby targets it for proteosomal degradation. Consistent with the up-regulation of beta-catenin levels, our results show that MUC1 blocks GSK3beta-mediated phosphorylation and degradation of beta-catenin. To further define the interaction between MUC1 and beta-catenin, we identified a serine-rich motif (SRM) in the MUC1 cytoplasmic domain that binds directly to beta-catenin Armadillo repeats. Mutation of the SRM attenuated binding of MUC1 to beta-catenin and MUC1-mediated inhibition of beta-catenin degradation. Importantly, disruption of the MUC1-beta-catenin interaction with the SRM mutant also attenuated MUC1-induced anchorage-dependent and -independent growth and delayed MUC1-mediated tumorigenicity. These findings indicate that MUC1 promotes transformation, at least in part, by blocking GSK3beta-mediated phosphorylation and thereby degradation of beta-catenin.

Citing Articles

Probiotic Bifidobacterium bifidum strains desialylate MUC13 and increase intestinal epithelial barrier function.

Segui-Perez C, Huang L, Paganelli F, Lievens E, Strijbis K Sci Rep. 2025; 15(1):8778.

PMID: 40082523 PMC: 11906825. DOI: 10.1038/s41598-025-92125-2.


Beyond BCMA: newer immune targets in myeloma.

Tan M, Chen Y, Smith E Blood Adv. 2024; 8(16):4433-4446.

PMID: 38865708 PMC: 11375259. DOI: 10.1182/bloodadvances.2023010856.


Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.

Ayyalasomayajula R, Cudic M Cancers (Basel). 2024; 16(7).

PMID: 38611013 PMC: 11011055. DOI: 10.3390/cancers16071334.


MUC13 negatively regulates tight junction proteins and intestinal epithelial barrier integrity via protein kinase C.

Segui-Perez C, Stapels D, Ma Z, Su J, Passchier E, Westendorp B J Cell Sci. 2024; 137(5).

PMID: 38345099 PMC: 10984281. DOI: 10.1242/jcs.261468.


Mucin 1 promotes salivary gland cancer cell proliferation and metastasis by regulating the epidermal growth factor receptor signaling pathway.

Lu H, Xu W, Wu Y, Yang W, Liu S J Dent Sci. 2023; 18(4):1651-1662.

PMID: 37799896 PMC: 10547961. DOI: 10.1016/j.jds.2023.01.035.